CheckMate 77T: Nivolumab Preserves Quality of Life and Mitigates Symptom Worsening in Resectable NSCLC
In a significant advancement for the treatment landscape of early-stage non-small cell lung cancer (NSCLC), new data from the pivotal Phase 3 CheckMate 77T trial...
















